Abbott Laboratories
Abbott Laboratories (ABT) Financial Performance & Income Statement Overview
Analyze Abbott Laboratories (ABT) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Abbott Laboratories (ABT) Income Statement & Financial Overview
Explore comprehensive income reports for Abbott Laboratories ABT, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $10.36B | $10.97B | $10.63B | $10.38B |
| Cost of Revenue | $4.47B | $4.94B | $4.70B | $4.57B |
| Gross Profit | $5.89B | $6.03B | $5.94B | $5.81B |
| Gross Profit Ratio | $0.57 | $0.55 | $0.56 | $0.56 |
| R&D Expenses | $716.00M | $754.00M | $713.00M | $698.00M |
| SG&A Expenses | $3.06B | $2.91B | $2.90B | $2.92B |
| Operating Expenses | $4.20B | $4.12B | $4.08B | $4.08B |
| Total Costs & Expenses | $8.66B | $9.06B | $8.78B | $8.65B |
| Interest Income | $82.00M | $91.00M | $91.00M | $82.00M |
| Interest Expense | $131.00M | $136.00M | $142.00M | $140.00M |
| Depreciation & Amortization | $756.00M | $807.00M | $801.00M | $805.00M |
| EBITDA | $2.67B | $2.99B | $2.91B | $2.64B |
| EBITDA Ratio | $0.26 | $0.27 | $0.27 | $0.25 |
| Operating Income | $1.69B | $1.91B | $1.86B | $1.72B |
| Operating Income Ratio | $0.16 | $0.17 | $0.17 | $0.17 |
| Other Income/Expenses (Net) | $85.00M | $119.00M | $81.00M | -$62.00M |
| Income Before Tax | $1.78B | $2.03B | $1.94B | $1.61B |
| Income Before Tax Ratio | $0.17 | $0.18 | $0.18 | $0.15 |
| Income Tax Expense | $453.00M | -$7.20B | $294.00M | $305.00M |
| Net Income | $1.32B | $9.23B | $1.65B | $1.30B |
| Net Income Ratio | $0.13 | $0.84 | $0.15 | $0.13 |
| EPS | $0.76 | $5.33 | $0.95 | $0.75 |
| Diluted EPS | $0.76 | $5.27 | $0.94 | $0.74 |
| Weighted Avg Shares Outstanding | $1.75B | $1.73B | $1.73B | $1.73B |
| Weighted Avg Shares Outstanding (Diluted) | $1.75B | $1.75B | $1.75B | $1.75B |
Financial performance has remained strong, with revenue growing from $10.38B in Q2 2024 to $10.36B in Q1 2025. Gross profit continued to perform well, with margins at 57% in the latest quarter. Operating income reached $1.69B in Q1 2025, holding a steady 16% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $2.67B. Net income dropped to $1.32B, keeping EPS at $0.76. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan